Failed ALTTO Breast Cancer Trial Casts Doubt On pCR Marker
This article was originally published in The Pink Sheet Daily
New surrogate marker used to speed development and approval of breast cancer drugs fails to match with better outcomes in ALTTO breast cancer study of Tykerb with Herceptin, featured in ASCO plenary session. Results have “profound implications” for drug development, says outgoing ASCO president Clifford Hudis.
You may also be interested in...
Five neoadjuvant breast cancer regimens have been tested successfully in I-SPY Phase II program, but three have not moved on to sponsor-driven pivotal testing and the I-SPY 3 master protocol has yet to be used.
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.
Despite concerns about accelerated approval on the basis of pathological complete response, which has not yet been correlated with improvements in longer-term outcomes, FDA panelists say the large body of efficacy and safety data supporting Genentech’s pertuzumab makes it worth the regulatory risk.